Dominari Proxy Seeks Votes on New Auditor, Poison-Pill Extension and $32.6M CEO Pay
DOMH is trading near its 52-week low of $1.68 (7.7% above the low).
Summary
Dominari's preliminary proxy asks shareholders to ratify new auditor Grassi, extend the poison pill to 2027, and approve 2025 pay of $32.6 million for the CEO and $30.4 million for the President — compensation that was mostly equity granted just before market-moving news.
Key Events · Corporate Governance and Compliance · DOMH
-
Annual Meeting Set for December 9
A virtual 2026 annual meeting will be held on December 9, 2026, with a record date of October 20, 2026 and 25,201,979 common shares outstanding. Four proposals are on the ballot: elect Blattner, Parsley and Wool as Class III directors, ratify Grassi as auditor, hold an advisory say-on-pay vote, and extend the Rights Agreement.
-
New Auditor Up for Ratification
CBIZ CPAs P.C. was dismissed on June 24, 2026, and Grassi & Co., CPAs, P.C. was engaged for fiscal 2026. CBIZ's reports for 2025 and 2024 carried no adverse opinion or disclaimer. Audit fees were $710,000 in 2025 versus $562,000 in 2024.
-
Poison Pill Extension to 2027
Proposal 4 extends the October 11, 2023 Rights Agreement from October 11, 2025 through October 11, 2027, with two additional 12-month renewals possible through October 11, 2029, each subject to shareholder approval. The pill is designed to protect net operating losses under Section 382 by discouraging 4.99% stakes.
-
CEO and President 2025 Pay
CEO Anthony Hayes' 2025 total compensation was $32,609,100 and President Kyle Wool's $30,416,667, versus $2,776,692 and $2,838,735 in 2024. Each received 5,000,000 options at a $6.16 exercise price plus large stock awards; the proxy states the grants were made just prior to announcing material nonpublic information, with a 74.26% post-disclosure price move.
Analysis · DOMH · Trade & Services
Shareholders face three governance items at the December 9 meeting: ratification of Grassi as auditor following CBIZ's dismissal on June 24, 2026; an extension of the poison pill through October 2027, with two more 12-month renewals possible to 2029; and a say-on-pay vote on 2025 compensation that paid CEO Anthony Hayes $32.6 million and President Kyle Wool $30.4 million. Nearly all of that pay is equity — each received 5,000,000 options struck at $6.16 plus large stock awards — and the proxy itself discloses the grants were timed just before the company announced material nonpublic information, after which the stock moved 74.26%. Set against a $62.8 million first-half net loss and $38.8 million of operating cash burn, the equity-heavy pay and insider ownership concentration (officers and directors hold 82.92%) are the real story for outside holders.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 39.1% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DOMH was trading at $1.81 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $43.9M. The 52-week trading range was $1.68 to $6.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.